Vivanza Biosciences Q1 FY27 results: PAT jumps to Rs 14.51 lakh

Pat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹1.89

prior close

₹1.89

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-0.0% vs market

Pharmaceuticals peers, median of 167sector+0.3%-0.3% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.0-0.0+0.3-0.3

Next day

-0.5-0.0-0.5+0.7-1.2

-0.5-0.2-0.3+0.6-1.1

+0.5+0.2+0.4+0.2+0.3

+5.3+0.3+5.0+1.2+4.1

+0.5+0.4+0.1+0.2+0.4

-6.3+0.9-7.3+0.2-6.6

15d

-8.5+1.6-10.0+1.4-9.8

-8.5+2.0-10.5+2.4-10.9

-7.9+0.6-8.5+1.8-9.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vivanza Biosciences reported Q1 FY27 standalone revenue of Rs 914.09 lakh, up about 17% YoY from Rs 782.06 lakh. Standalone PAT surged to Rs 14.51 lakh from Rs 1.86 lakh in Q1 FY26. Total income stood at Rs 951.37 lakh. Consolidated revenue was Rs 928.97 lakh with PAT of Rs 14.67 lakh. Board approved unaudited results with a clean limited review report and no adverse observations. Company operates in pharma, agro and film segments.

Likely market impact

Strong profit growth signals improving operations, though off a low base. Consolidated revenue growth was modest at about 4% YoY.